Patterns of response to therapy of imatinib-resistant CML
| . | CP . | AP . | BP/ALL . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total . | Dasatinib . | Nilotinib . | P . | Total . | Dasatinib . | Nilotinib . | P . | Total . | Dasatinib† . | Nilotinib† . | |
| Response* | n=38 | n=24 | n=13 | n=54 | n=22 | n=31 | n=20 | n=10 | n=10 | ||
| Hematologic | 31 (82) | 21 (87) | 10 (77) | .64 | 42 (78) | 16 (73) | 26 (84) | .49 | 11 (55) | 6 (60) | 5 (50) |
| CHR | 30 (79) | 20 (84) | 10 (77) | .68 | 40 (74) | 14 (64) | 26 (84) | .11 | 9 (45) | 4 (40) | 5 (50) |
| Cytogenetic | 21 (55) | 15 (62) | 6 (46) | .49 | 18 (33) | 5 (23) | 13 (42) | .24 | 7 (35) | 4 (40) | 3 (30) |
| Complete | 10 (26) | 8 (32) | 2 (15) | .44 | 11 (20) | 3 (14) | 8 (26) | .33 | 7 (35) | 4 (40) | 3 (30) |
| Major | 16 (42) | 12 (50) | 4 (34) | .31 | 14 (26) | 4 (19) | 10 (33) | .35 | 7 (35) | 4 (40) | 3 (30) |
| . | CP . | AP . | BP/ALL . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total . | Dasatinib . | Nilotinib . | P . | Total . | Dasatinib . | Nilotinib . | P . | Total . | Dasatinib† . | Nilotinib† . | |
| Response* | n=38 | n=24 | n=13 | n=54 | n=22 | n=31 | n=20 | n=10 | n=10 | ||
| Hematologic | 31 (82) | 21 (87) | 10 (77) | .64 | 42 (78) | 16 (73) | 26 (84) | .49 | 11 (55) | 6 (60) | 5 (50) |
| CHR | 30 (79) | 20 (84) | 10 (77) | .68 | 40 (74) | 14 (64) | 26 (84) | .11 | 9 (45) | 4 (40) | 5 (50) |
| Cytogenetic | 21 (55) | 15 (62) | 6 (46) | .49 | 18 (33) | 5 (23) | 13 (42) | .24 | 7 (35) | 4 (40) | 3 (30) |
| Complete | 10 (26) | 8 (32) | 2 (15) | .44 | 11 (20) | 3 (14) | 8 (26) | .33 | 7 (35) | 4 (40) | 3 (30) |
| Major | 16 (42) | 12 (50) | 4 (34) | .31 | 14 (26) | 4 (19) | 10 (33) | .35 | 7 (35) | 4 (40) | 3 (30) |
Data are number (percent in all but the P columns. For BP/ALL, all P values were .999.
CP indicates chronic phase; AP, accelerated phase; BP, blastic phase; ALL, Ph-positive acute lymphocytic leukemia; and CHR, complete hematologic response.
Two patients were treated with bosutinib: one in CP achieved partial hematologic response and one in AP achieved a minor cytogenetic response.
Eight patients with myeloid blast phase and 2 patients with lymphoid blast phase received nilotinib; 7 patients with myeloid blast phase and 3 patients with lymphoid blast phase received dasatinib.